Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANDCAP1: Inhaled Levofloxacin for Community Acquired Pneumonia
NCT06859450Phase 3Not yet recruiting
- Sponsor
- Copenhagen Respiratory Research
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of Levofloxacin inhalation solution in community acquired pneumonia (CAP) (6 arms), sponsored by Copenhagen Respiratory Research. Primary endpoint: Change in Forced Expiratory Volume in 1 second after first inhalation. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
Levofloxacin inhalation solution
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT06859450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859450.